急性呼吸窮迫症候群（ARDS）の世界市場レポート 2025年

急性呼吸窮迫症候群（ARDS）市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.1％で21億7,000万米ドルに成長します。予測期間の成長は、世界のヘルスケアへの備え、ワクチン開発と感染症管理、遠隔医療と遠隔モニタリング、患者中心のケアモデルに起因しています。予測期間における主な動向には、人工肺装置、個別化された換気戦略、肺保護換気、肺炎サブタイプに対する薬物療法などがあります。

肺炎の有病率の増加が急性呼吸窮迫症候群（ARDS）市場の成長を牽引すると予測されます。肺炎は、片方または両方の肺を侵し、肺胞（肺の気嚢）に液体や膿が蓄積する感染症です。これは、血管透過性を増加させる炎症反応を引き起こし、液体が肺胞に漏れ、酸素と二酸化炭素の交換が損なわれ、呼吸困難を引き起こします。例えば、2023年11月、英国を拠点とするヘルスケア研究のリーダーである熱帯医学・世界ヘルスセンターは、ケニアにおける肺炎患者の大幅な増加を報告し、その数は2020-2021年の477,186人から2022-2023年には793,864人に増加しました。その結果、肺炎の有病率の増加がARDS市場の拡大を促進しています。

呼吸器疾患の罹患率の上昇は、急性呼吸窮迫症候群（ARDS）市場の成長を促進すると予想されます。呼吸器疾患には、気道や肺に影響を及ぼし、しばしば呼吸困難を引き起こすさまざまな病状が含まれます。COVID-19を含む呼吸器疾患の増加は、ARDS市場の成長に寄与する重要な要因です。呼吸器疾患を発症する人が増えるにつれて、ARDSの治療や療法に対する需要が高まり、市場の拡大を後押しする可能性が高いです。例えば、2023年11月、米国の政府機関である労働統計局によると、2022年、民間企業の雇用者の発病率は、フルタイム換算（FTE）労働者1万人当たり45.2件となり、2021年の37.7件から増加しました。この増加の主な原因は呼吸器疾患の増加であり、2021年のFTE労働者1万人当たり27.8件から2022年には35.8件に急増しました。したがって、呼吸器疾患の増加がARDS市場の拡大を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界急性呼吸窮迫症候群（ARDS） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の急性呼吸窮迫症候群（ARDS）市場：成長率分析
• 世界の急性呼吸窮迫症候群（ARDS）市場の実績：規模と成長, 2019-2024
• 世界の急性呼吸窮迫症候群（ARDS）市場の予測：規模と成長, 2024-2029, 2034F
• 世界急性呼吸窮迫症候群（ARDS）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性呼吸窮迫症候群（ARDS）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断
• 治療
• 世界の急性呼吸窮迫症候群（ARDS）市場原因別、実績と予測, 2019-2024, 2024-2029F, 2034F
• COVID-19感染症2019（COVID-19）
• 敗血症
• 有害物質の吸入
• 重度の肺炎
• その他の原因
• 世界の急性呼吸窮迫症候群（ARDS）市場重症度別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽度
• 適度
• 厳しい
• 世界の急性呼吸窮迫症候群（ARDS）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 外来サービスセンター
• その他のエンドユーザー
• 世界の急性呼吸窮迫症候群（ARDS）市場、診断のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 画像検査
• 血液検査
• 肺機能検査
• その他の診断方法
• 世界の急性呼吸窮迫症候群（ARDS）市場、治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 機械的人工呼吸器
• 医薬品
• 体外式膜型人工肺（ECMO）
• 支持療法
• その他の治療オプション

第7章 地域別・国別分析

• 世界の急性呼吸窮迫症候群（ARDS）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の急性呼吸窮迫症候群（ARDS）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性呼吸窮迫症候群（ARDS）市場：競合情勢
• 急性呼吸窮迫症候群（ARDS）市場：企業プロファイル
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Gilead Sciences Inc.
• Amgen Inc.
• Fresenius SE & Co. KGaA
• Koninklijke Philips N.V.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• CSL Behring
• Terumo Corporation
• ResMed Inc.
• Smiths Medical Inc.
• Drager Safety AG & Co. KGaA.
• Getinge AB
• Mallinckrodt plc
• Masimo Corporation
• United Therapeutics Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 急性呼吸窮迫症候群（ARDS）市場2029：新たな機会を提供する国
• 急性呼吸窮迫症候群（ARDS）市場2029：新たな機会を提供するセグメント
• 急性呼吸窮迫症候群（ARDS）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acute Respiratory Distress Syndrome (ARDS) is a potentially life-threatening condition characterized by rigid, non-compliant lungs and inadequate oxygenation. This condition presents as an acute, widespread inflammatory lung injury that can affect critically ill patients. The primary approach to treating ARDS involves employing mechanical ventilation with low tidal volumes and positive end-expiratory pressure (PEEP) to support oxygen levels and minimize further lung damage.

The key facets of dealing with Acute Respiratory Distress Syndrome (ARDS) pertain to its diagnosis and treatment. Diagnosis encompasses the process of distinguishing this condition from other potential disorders and delineating its characteristics. The diagnosis of ARDS typically relies on a physical examination, chest X-ray, and oxygenation levels. ARDS can be triggered by various factors such as COVID-19 (COVID-19 Disease 2019), sepsis, exposure to harmful substances, severe pneumonia, among others, with its severity ranging from mild to moderate and severe. The primary recipients of ARDS-related services include hospitals, clinics, ambulatory service centers, and other healthcare facilities.

The acute respiratory distress syndrome (ARDS) market research report is one of a series of new reports from The Business Research Company that provides acute respiratory distress syndrome (ARDS) market statistics, including acute respiratory distress syndrome (ARDS) industry global market size, regional shares, competitors with an acute respiratory distress syndrome (ARDS) market share, detailed acute respiratory distress syndrome (ARDS) market segments, market trends and opportunities and any further data you may need to thrive in the acute respiratory distress syndrome (ARDS) industry. This acute respiratory distress syndrome (ARDS) market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute respiratory distress syndrome (ARDS) market size has grown rapidly in recent years. It will grow from $1.29 billion in 2024 to $1.42 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to advancements in critical care medicine, aging population, pulmonary rehabilitation, multidisciplinary care teams.

The acute respiratory distress syndrome (ARDS) market size is expected to see rapid growth in the next few years. It will grow to $2.17 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to global healthcare preparedness, vaccine development and infectious disease management, telemedicine and remote monitoring, patient-centered care models. Major trends in the forecast period include artificial lung devices, personalized ventilation strategies, lung protective ventilation, drug therapies for ards subtypes.

The increasing prevalence of pneumonia is expected to drive the growth of the acute respiratory distress syndrome (ARDS) market. Pneumonia is an infection that affects one or both lungs, leading to the accumulation of fluid or pus in the alveoli, or air sacs of the lungs. This causes an inflammatory reaction that increases blood vessel permeability, allowing fluid to leak into the alveoli and impairing the exchange of oxygen and carbon dioxide, resulting in respiratory distress. For example, in November 2023, the Centre for Tropical Medicine and Global Health, a UK-based leader in healthcare research, reported a significant rise in pneumonia cases in Kenya, which increased from 477,186 in 2020-2021 to 793,864 in 2022-2023. As a result, the growing prevalence of pneumonia is driving the expansion of the ARDS market.

The rising incidence of respiratory illnesses is expected to drive the growth of the acute respiratory distress syndrome (ARDS) market. Respiratory illnesses encompass a range of medical conditions that affect the airways and lungs, often causing difficulty in breathing. The increasing number of respiratory illnesses, including COVID-19, is a significant factor contributing to the growth of the ARDS market. As more individuals develop respiratory conditions, the demand for ARDS treatments and therapies is likely to rise, boosting market expansion. For instance, in November 2023, the Bureau of Labor Statistics, a US-based government agency, reported that in 2022, the illness rate among private industry employers increased to 45.2 cases per 10,000 full-time equivalent (FTE) workers, up from 37.7 cases in 2021. This increase was largely attributed to a rise in respiratory illnesses, which jumped from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Therefore, the growing number of respiratory illnesses is driving the expansion of the ARDS market.

Prominent companies operating within the acute respiratory distress syndrome (ARDS) market are dedicating their efforts to the creation of groundbreaking drugs and supplements, including Aviptadil and HSP90 inhibitors, aimed at reinforcing their market position. Aviptadil, a synthetic vasoactive intestinal peptide (VIP), is designed to specifically target receptors on lung alveolar type II cells. For instance, in November 2022, Zuventus Healthcare Ltd., an Indian pharmaceutical manufacturing company, introduced Aviptadil as a treatment for acute respiratory distress syndrome. Aviptadil, functioning as a vasoactive intestinal peptide supplement, enhances breathing and reduces mortality in ARDS patients. This is achieved through Aviptadil's capacity to safeguard and regenerate Type-2 Pneumocytes, restore Type-1 Pneumocytes, increase surfactant synthesis, and suppress interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).

In January 2022, AcelRx Pharmaceuticals Inc., a specialized pharmaceutical company based in the United States, acquired Lowell Therapeutics Inc. for $32.5 million. This strategic acquisition empowers AcelRx Pharmaceuticals to expand its product portfolio and solidify its standing in the pharmaceutical industry. Lowell Therapeutics Inc., also based in the U.S., is a pharmaceutical company dedicated to developing products for the treatment of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC).

Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Drager Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute respiratory distress syndrome (ARDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute respiratory distress syndrome (ARDS) market includes revenues earned by entities by providing resolution and recovery services, medication, supplemental oxygen and mechanical ventilation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute respiratory distress syndrome (ARDS) market consists of sales of neuromuscular blockers, corticosteroids, monitoring devices, diagnostic devices and therapeutic devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute respiratory distress syndrome (ards) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute respiratory distress syndrome (ards) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute respiratory distress syndrome (ards) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Diagnosis; Treatment
• 2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes
• 3) By Severity: Mild; Moderate; Severe
• 4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users
• Subsegments:
• 1) By Diagnosis: Imaging Tests; Blood Tests; Lung Function Tests; Other Diagnostic Methods
• 2) By Treatment: Mechanical Ventilation; Medications; Extracorporeal Membrane Oxygenation (ECMO); Supportive Care; Other Treatment Options
• Companies Mentioned: Johnson & Johnson Services Inc.; Novartis AG; GlaxoSmithKline plc; Medtronic plc; Boehringer Ingelheim International GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Respiratory Distress Syndrome (ARDS) Market Characteristics

3. Acute Respiratory Distress Syndrome (ARDS) Market Trends And Strategies

4. Acute Respiratory Distress Syndrome (ARDS) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Acute Respiratory Distress Syndrome (ARDS) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Respiratory Distress Syndrome (ARDS) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Respiratory Distress Syndrome (ARDS) Market Growth Rate Analysis
• 5.4. Global Acute Respiratory Distress Syndrome (ARDS) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Respiratory Distress Syndrome (ARDS) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Respiratory Distress Syndrome (ARDS) Total Addressable Market (TAM)

6. Acute Respiratory Distress Syndrome (ARDS) Market Segmentation

• 6.1. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnosis
• Treatment
• 6.2. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• COVID-19 Disease 2019 (COVID-19)
• Sepsis
• Inhalation Of Harmful Substances
• Severe Pneumonia
• Other Causes
• 6.3. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild
• Moderate
• Severe
• 6.4. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Service Centers
• Other End Users
• 6.5. Global Acute Respiratory Distress Syndrome (ARDS) Market, Sub-Segmentation Of Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Tests
• Blood Tests
• Lung Function Tests
• Other Diagnostic Methods
• 6.6. Global Acute Respiratory Distress Syndrome (ARDS) Market, Sub-Segmentation Of Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mechanical Ventilation
• Medications
• Extracorporeal Membrane Oxygenation (ECMO)
• Supportive Care
• Other Treatment Options

7. Acute Respiratory Distress Syndrome (ARDS) Market Regional And Country Analysis

• 7.1. Global Acute Respiratory Distress Syndrome (ARDS) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Respiratory Distress Syndrome (ARDS) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market

• 8.1. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Respiratory Distress Syndrome (ARDS) Market

• 9.1. China Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 9.2. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Respiratory Distress Syndrome (ARDS) Market

• 10.1. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Respiratory Distress Syndrome (ARDS) Market

• 11.1. Japan Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 11.2. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Respiratory Distress Syndrome (ARDS) Market

• 12.1. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market

• 13.1. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Respiratory Distress Syndrome (ARDS) Market

• 14.1. South Korea Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 14.2. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market

• 15.1. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 15.2. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Respiratory Distress Syndrome (ARDS) Market

• 16.1. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Respiratory Distress Syndrome (ARDS) Market

• 17.1. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Respiratory Distress Syndrome (ARDS) Market

• 18.1. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Respiratory Distress Syndrome (ARDS) Market

• 19.1. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Respiratory Distress Syndrome (ARDS) Market

• 20.1. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market

• 21.1. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 21.2. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Respiratory Distress Syndrome (ARDS) Market

• 22.1. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Respiratory Distress Syndrome (ARDS) Market

• 23.1. North America Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 23.2. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Respiratory Distress Syndrome (ARDS) Market

• 24.1. USA Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 24.2. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Respiratory Distress Syndrome (ARDS) Market

• 25.1. Canada Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 25.2. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Respiratory Distress Syndrome (ARDS) Market

• 26.1. South America Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 26.2. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Respiratory Distress Syndrome (ARDS) Market

• 27.1. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Respiratory Distress Syndrome (ARDS) Market

• 28.1. Middle East Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 28.2. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Respiratory Distress Syndrome (ARDS) Market

• 29.1. Africa Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 29.2. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Respiratory Distress Syndrome (ARDS) Market Competitive Landscape And Company Profiles

• 30.1. Acute Respiratory Distress Syndrome (ARDS) Market Competitive Landscape
• 30.2. Acute Respiratory Distress Syndrome (ARDS) Market Company Profiles
  • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

31. Acute Respiratory Distress Syndrome (ARDS) Market Other Major And Innovative Companies

• 31.1. Gilead Sciences Inc.
• 31.2. Amgen Inc.
• 31.3. Fresenius SE & Co. KGaA
• 31.4. Koninklijke Philips N.V.
• 31.5. Baxter International Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. CSL Behring
• 31.8. Terumo Corporation
• 31.9. ResMed Inc.
• 31.10. Smiths Medical Inc.
• 31.11. Drager Safety AG & Co. KGaA.
• 31.12. Getinge AB
• 31.13. Mallinckrodt plc
• 31.14. Masimo Corporation
• 31.15. United Therapeutics Corporation

32. Global Acute Respiratory Distress Syndrome (ARDS) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Respiratory Distress Syndrome (ARDS) Market

34. Recent Developments In The Acute Respiratory Distress Syndrome (ARDS) Market

35. Acute Respiratory Distress Syndrome (ARDS) Market High Potential Countries, Segments and Strategies

• 35.1 Acute Respiratory Distress Syndrome (ARDS) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Respiratory Distress Syndrome (ARDS) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Respiratory Distress Syndrome (ARDS) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer